KOMO Biosciences’ recent announcement of a research license agreement with Caravan Biologix for the KOMbine™ gene editing platform has received broad coverage across national biotech and financial news outlets. The release, distributed via Business Wire, has been published by over 190 media platforms across the United States, reflecting strong interest in KOMO’s proprietary technology and its applications in next-generation gene and cell therapies.
Selected media highlights include:
- BioSpace
- San Francisco Biotech Networks
- Boston Cambridge Biotech Networks
- Morningstar
- StreetInsider
- Yahoo! Finance
This milestone reflects growing industry interest in the KOMbine™ targeted gene insertion platform and its potential to accelerate the development of next-generation processes and therapeutics.